| 摘要 |
The present invention refers to the use of at least one tricyclic diterpenes for the manufacture of a cosmetic, nutraceutical or pharmaceutical for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders. More particularly, the compounds are selected from 7-oxodehydroabietic acid, totarol, hydroxytotarol, totarol-19-carboxylic acid methyl ester, sageone, 8,11,13-abietatriene-11,12,20-triol, royleanonic acid, ferruginol, carnosic acid 12-methylether and 7-methylrosmanol. |
